TITLE

NDA for ritonavir

PUB. DATE
February 1996
SOURCE
Drug Topics;2/5/96, Vol. 140 Issue 3, p28
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports on the submission of a New Drug Application by Abbott Laboratories for the ritonavir protease inhibitor.
ACCESSION #
9602252844

 

Related Articles

  • Diabetes, protease-inhibitor link unproved: directorate.  // CMAJ: Canadian Medical Association Journal;09/01/97, Vol. 157 Issue 5, p502 

    States that the Therapeutic Drugs Directorate at Health Canada find no conclusive evidence to support a causal relationship between protease inhibitors and diabetes or hyperglycemia in HIV-infected patients.

  • Combination of two protease inhibitors reduces HIV viral load by 99.9%.  // AIDS Patient Care & STDs;Dec96, Vol. 10 Issue 6, p375 

    Reports on the reduction of HIV viral load of 99.9 percent by combining two protease inhibitors. Effects of the protease inhibitors.

  • Compliance and dosage critical in HIV suppression by protease inhibition.  // AIDS Patient Care & STDs;Dec96, Vol. 10 Issue 6, p377 

    Reports that starting and maintaining protease inhibitor therapy at the recommended dosages delays the development of resistant HIV virus and assists in long-term viral suppression. Presentation of indinavir (Crixivan) data.

  • Editorial Response: Discordance between Virological, Immunologic, and Clinical Outcomes of Therapy with Protease Inhibitors among Human Immunodeficiency Virus-Infected Patients. Goetz, Matthew Bidwell // Clinical Infectious Diseases;12/1/1999, Vol. 29 Issue 6, p1431 

    Comments on the findings of I. Mezzaroma, M. Carlesimo, E. Pinter et al on the occurrence of discordant virological and immunologic responses among HIV-infected patients who had received protease inhibitor-based antiretroviral therapy, published in the December 1999 issue of the journal...

  • Ritonavir for advanced HIV infection.  // American Family Physician;7/1/1996, Vol. 54 Issue 1, p372 

    Reports that the United States Food and Drug Administration has approved the protease inhibitor ritonavir for the treatment of patients with human immunodeficiency virus (HIV) infection. Combination of ritonavir with nucleoside analogs or as monotherapy; Clinical trials on the efficacy of...

  • From the Archives of The Advocate. Romesburg, Don // Advocate;05/23/2000, Issue 812, p22 

    Reports on the use of protease inhibitors to treat AIDS. Side effects; Complications of patients whose lives have been extended by treatment; Coverage of the development by `Advocate' magazine.

  • Initial Therapy with Protease Inhibitor--Sparing Regimens: Evaluation of Nevirapine and Delavirdine. Conway, Brain // Clinical Infectious Diseases;6/1/2000 Supplement 2, Vol. 30, pS130 

    Evaluates the results of randomized clinical trials of protease inhibitor-sparing regimens in drug-naive patients. Mean decrease in plasma viral load in patients receiving the zidovudine, didanosine and nevirapine combined therapy; Increased CD4 T cell count, indicating the immunologic benefit...

  • HIV Protease Inhibitor--Related Lipodystrophy Syndrome. Carr, Andrew // Clinical Infectious Diseases;6/1/2000 Supplement 2, Vol. 30, pS135 

    Explores the association of HIV protease inhibitor (PI) therapy with lipodystrophy syndrome. Occurrence of peripheral lipoatrophy during the course of the therapy; Asymptomatic and nonketotic clinical presentation in diabetes associated with PI therapy; Abnormal lipodystrophy and metabolic...

  • HIV-1 Protease Inihibitors. Eron Jr., Joseph J. // Clinical Infectious Diseases;6/1/2000 Supplement 2, Vol. 30, pS160 

    Focuses on the role of protease inhibitors (PI) in the antiretroviral therapy for HIV-1 infected patients. Potent activity in vitro of five United States Food and Drug Administration-approved PI agents; Suppression of HIV-1 replication by PI agents with two nucleoside analogue reverse...

  • Determinants of Virological Response to Antiretroviral Therapy: Implications for Long-Term... Deeks, Steven G. // Clinical Infectious Diseases;6/1/2000 Supplement 2, Vol. 30, pS177 

    Discusses the determinants of virological failure in protease inhibitor-including regimen for treatment of HIV infections. Potency of existing regimens; Baseline CD4[sup +] T cell count and viral load; Pre-existing viral resistance; Medication adherence; Pharmacokinetics; Role of viral...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics